Selvita is a Polish biotechnological company operating within the area of the invention and development of drugs used mainly...
It also deals with providing research and development services and construction of IT solutions supporting innovative projects.
Selvita was established in 2007. Currently, it employs more than 380 employees, 1/3 of which hold a doctoral degree. The main seat of the Company and laboratories are located in Kraków. Selvita has offices in the largest biotechnological centers throughout the world, in the Boston region and San Francisco region in United States, as well as in Cambridge in Great Britain.
In the field of research on cancers, the Company cooperates with renowned foreign companies like H3 Biomedicine, Merck, Nodthera and Felicitex Therapeutics.
Selvita is listed on the Stock Exchange in Warsaw (SLV) since December 2014. In March 2017 it was listed on sWIG80 index.